Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients

Cirrhosis Clinical Trial

— CirCo  

Official title:

Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04490330
• Other study ID #: PI2019_843_0106
• Status: Recruiting
• Start date: August 1, 2020
• Est. completion date: August 2023

Study information

• Verified date: February 2023
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: Bernard ANGERVILLE, MD
• Phone: (33)322068297
• Email: angerville.bernard[@]chu-amiens.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

80% of patients with alcohol use disorders (AUD) present cognitive impairments, such as memory and executive functions. These disorders may have repercussions in addiction treatment by altering the patient's adherence to care. The level of impairment is dependent on the onset of addiction, and also the duration of abstinence.

A complete neuropsychological evaluation is necessary to highlight cognitive impairments. In practice, the evaluation of these disorders by practitioners, is done with the help of tools of screening like the MoCa (Montreal cognitive assesment) and the BEARNI (Brief evaluation of alcohol related neuropsychological impairment).

However, none of these tools have been evaluated in patients with alcoholic cirrhosis. Indeed, some studies have suggested that liver disorders including cirrhosis may be a factor aggravating cognitive disorders.

The purpose of this study is to evaluate the ability of the BEARNI tool to detect alcohol-related cognitive problems in patients with alcohol-related cirrhosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: August 2023
• Est. primary completion date: August 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient with cirrhosis

• patients with cirrhosis diagnosed by clinical examination

• patients with cirrhosis diagnosed by biological and / or morphological and / or noninvasive tests and / or liver biopsy

• CHILD A, B or C

Exclusion Criteria:

• hepatitis encephalopathy less than 6 months old

• complicated cirrhosis with hepatocellular carcinoma

• Acute alcoholic hepatitis

• viral cirrhosis

Related Conditions & MeSH terms

• Alcohol Dependence
• Alcoholism
• Cirrhosis
• Cognitive Dysfunction
• Cognitive Impairments
• Dependence
• Fibrosis
• Liver Diseases

Intervention

Other:
• questionnaire
AUDIT questionnaire (alcohol use disorders identification test)

Locations

Country	Name	City	State
France	CHU Amiens	Amiens

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of alcoholic cirrhosis patients with presence of alcohol-related cognitive disorders	the number of alcoholic cirrhosis patients with presence of alcohol-related cognitive disorders will be measured by using the BEARNI screening tool. BEARNI screening tool is Brief evaluation of alcohol related neuropsychological impairment.	day 1